InsiderTrades.com logo
What The White House Is NOT Telling You About The "Green Revolution."
From Investing Trends   |   Ad
Governments across the globe want to go "All Electric" by 2035. There's one rare metal that could cripple these plans. Without it, going green is impossible. And that's why there's a modern-day gold-rush for this rare metal.
Read The Full Story On This "Gold Rush"

ELDN Insider Trading (Eledon Pharmaceuticals)

Insider Ownership Percentage: 6.10%
Insider Buying (Last 12 Months): $48,870.00
Insider Selling (Last 12 Months): $0.00

Eledon Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Eledon Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Eledon Pharmaceuticals Share Price & Price History

Current Price: $5.47
Price Change: ▼ Price Decrease of -0.03 (-0.55%)
As of 10/19/2021 01:00 AM ET

This chart shows the closing price history over time for ELDN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
What The White House Is NOT Telling You About The "Green Revolution."
From Investing Trends   |   Ad
Governments across the globe want to go "All Electric" by 2035. There's one rare metal that could cripple these plans. Without it, going green is impossible. And that's why there's a modern-day gold-rush for this rare metal.
Read The Full Story On This "Gold Rush"

Eledon Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/17/2021David-Alexandre C. GrosCEOBuy4,000$6.21$24,840.007,000View SEC Filing Icon  
6/9/2021David-Alexandre C. GrosCEOBuy3,000$8.01$24,030.003,000View SEC Filing Icon  
See Full Table
Insider Selling at Eledon Pharmaceuticals?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Eledon Pharmaceuticals and related companies.

SEC Filings (Institutional Ownership Changes) for Eledon Pharmaceuticals (NASDAQ:ELDN)

65.90% of Eledon Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ELDN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Eledon Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/23/2021Morgan Stanley851,004$6.73M0.0%+7,235.6%5.948%Search for SEC Filing on Google Icon
8/18/2021Ikarian Capital LLC350,000$2.77M0.2%+40.0%2.446%Search for SEC Filing on Google Icon
8/17/2021Woodline Partners LP857,445$6.78M0.1%-3.8%5.993%Search for SEC Filing on Google Icon
8/17/2021Millennium Management LLC17,993$0.14M0.0%+23.3%0.126%Search for SEC Filing on Google Icon
8/17/2021Boothbay Fund Management LLC40,052$0.32M0.0%+39.6%0.280%Search for SEC Filing on Google Icon
8/16/2021Point72 Asset Management L.P.188,690$1.49M0.0%+51.0%1.319%Search for SEC Filing on Google Icon
8/16/2021Morgan Stanley851,004$6.73M0.0%+7,235.6%5.948%Search for SEC Filing on Google Icon
8/16/2021State Street Corp32,935$0.26M0.0%N/A0.230%Search for SEC Filing on Google Icon
8/13/2021Renaissance Technologies LLC21,107$0.17M0.0%-22.0%0.148%Search for SEC Filing on Google Icon
8/13/2021Northern Trust Corp32,116$0.25M0.0%+106.8%0.224%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC124,614$0.99M0.0%+25.7%0.871%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.209,750$1.66M0.0%-8.8%1.466%Search for SEC Filing on Google Icon
5/19/2021Logos Global Management LP224,071$2.40M0.2%N/A1.566%Search for SEC Filing on Google Icon
5/18/2021BVF Inc. IL1,113,435$11.91M0.4%N/A7.782%Search for SEC Filing on Google Icon
5/18/2021Millennium Management LLC14,588$0.16M0.0%N/A0.102%Search for SEC Filing on Google Icon
5/18/2021Point72 Asset Management L.P.125,000$1.34M0.0%N/A0.874%Search for SEC Filing on Google Icon
5/18/2021Morgan Stanley11,601$0.12M0.0%N/A0.081%Search for SEC Filing on Google Icon
5/18/2021Cormorant Asset Management LP1,415,500$15.15M0.3%N/A9.894%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC25,062$0.27M0.0%N/A0.175%Search for SEC Filing on Google Icon
5/17/2021Woodline Partners LP891,055$9.53M0.2%N/A6.228%Search for SEC Filing on Google Icon
5/17/2021EcoR1 Capital LLC1,115,721$11.94M0.5%N/A7.798%Search for SEC Filing on Google Icon
5/17/2021Janus Henderson Group PLC213,899$2.25M0.0%N/A1.495%Search for SEC Filing on Google Icon
5/17/2021Ikarian Capital LLC250,000$2.68M0.1%N/A1.747%Search for SEC Filing on Google Icon
5/13/2021Renaissance Technologies LLC27,051$0.29M0.0%N/A0.189%Search for SEC Filing on Google Icon
5/12/2021Northern Trust Corp15,528$0.17M0.0%N/A0.109%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC99,123$1.06M0.0%N/A0.693%Search for SEC Filing on Google Icon
5/12/2021CM Management LLC75,000$0.80M0.6%N/A0.524%Search for SEC Filing on Google Icon
5/7/2021BlackRock Inc.12,282$0.13M0.0%N/A0.086%Search for SEC Filing on Google Icon
4/21/2021Ingalls & Snyder LLC51,149$0.55M0.0%N/A0.358%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm's compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation, making it a candidate for therapeutic intervention in transplant tolerance, autoimmune disease, and neuro-inflammation. The company is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies with AT-1501. Eledon Pharmaceuticals was founded on March 26, 2004 and is headquartered in Irvine, CA.
Read More on Eledon Pharmaceuticals

Today's Range

Now: $5.47
Low: $5.44
High: $5.81

50 Day Range

MA: $6.75
Low: $5.50
High: $8.46

52 Week Range

Now: $5.47
Low: $5.10
High: $27.32

Volume

22,199 shs

Average Volume

64,183 shs

Market Capitalization

$78.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.09

Who are the company insiders with the largest holdings of Eledon Pharmaceuticals?

Eledon Pharmaceuticals' top insider shareholders include:
  1. David-Alexandre C Gros (CEO)
  2. David-Alexandre C Gros (CEO)
  3. Paul Sean Little (CFO)
What The White House Is NOT Telling You About The "Green Revolution."
From Investing Trends   |   Ad
Governments across the globe want to go "All Electric" by 2035. There's one rare metal that could cripple these plans. Without it, going green is impossible. And that's why there's a modern-day gold-rush for this rare metal.
Read The Full Story On This "Gold Rush"